HW321005 / Humanwell Healthcare - LARVOL DELTA

Identification of a potent and selective KAT6A/6B inhibitor: HW321005 exhibits strong antitumor activity in KAT6A-high ER+/HER2− breast cancer (AACR 2025) - "These findings highlight the potential of HW321005 as a novel and highly effective KAT6A/6B inhibitor for the treatment of KAT6A-high ER+ breast cancer. IND-enabling studies for HW321005 are planned for early 2025."

Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • KAT6A • KAT6B